Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

By J. Bridgewater, Peter R. Galle, Shahid A. Khan, J. Llovet, Joong-Won Park, Tushar C. Patel, T. Pawlik, G. Gores. Journal of Hepatology, 2014

1,356 citations recorded by the source corpus.

varies substantially world-wide with the highest known rates in Northeast Thailand (>80 per 100,000 population) and much lower rates in the Western world, for example Canada (0.3 per 100,000) (Fig. 1) [8]. iCCA is the second most common primary liver cancer in humans, after hepatocellular carcinoma (HCC). Although the frequency of iCCA worldwide is considerably less than HCC, of note, several recent studies from around the world have reported rapidly rising rates of iCCA over the last few decades [9–11]

Subfields: Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/09c72f9f258e1707cbe4a3de58acf6930f6f62e7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Sumera I. Ilyas
2. G. Gores

In Surgery

1. Sumera I. Ilyas
2. Jordi Bruix1 , 2
3. G. Gores

Citations in the corpus

• EASL Clinical Practice Guidelines: Liver transplantation. (2016, background): “LT for cholangiocarcinoma remains a controversial issue due to a high risk of recurrence [87].”
• Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, neutral): “Reassuringly, in the phase I/II CheckMate 040 trial 159 , the incidence of grade 3 or 4 immune­mediated transaminase elevation among 214 patients with HCC who received the PD­1 inhibitor nivolumab was approximately 4% (similar to the rates reported for patients with other tumour types), without any ”
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management (2020, positive): “…include the unknown effects of improved diagnostics (imaging, endoscopy, histology), greater awareness and the acceptance of performing a biopsy even when imaging is highly suggestive of HCC (in accordance with current guidelines), and increasing the detection of combined HCC–CCA or iCCAs 3,24–28 .”
• The immunology of hepatocellular carcinoma (2018, background): “The frequency of other mutations, including those in the genes encoding the tumor suppressor p53 and cell-cycle regulators, as well as molecules involved in WNT–β -catenin signaling, epigenetic modification, oxidative-stress pathways, and the RAS–RAF– MAPK and PI(3)K–AKT–mTOR pathways2,125,126, depe”